Cryo-Cell International (CCEL) AI Stock Analysis

• Market Cap: $40.77M
• Dividend Yield: 9.91%
• Average Volume (3M): 10.84K
• Price to Earnings (P/E): 403.6
• Beta (1Y): -0.06
• Revenue Growth: 2.33%
• EPS Growth: N/A
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Care Facilities
• EPS (TTM): 0.01
• Shares Outstanding: 8,082,159
• 10 Day Avg. Volume: 8,017
• 30 Day Avg. Volume: 10,843
• PEG Ratio: -3.86
• Price to Book (P/B): -2.67
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 9.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $8.50
• Price Target Upside: 68.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Cryo-Cell International's overall stock score is impacted by moderate financial performance, highlighted by strong cash flow but significant balance sheet issues, including negative equity. The technical analysis indicates a bearish trend, which, combined with overvaluation concerns, further pressures the stock. The recent decision to reduce the dividend signals cautious financial management, contributing to a lower score.

Positive Factors

Business Model

Cryo-Cell's business model is highly appealing due to its mostly recurring revenues and positive cash flow generation.

Dividend

The company maintains a high dividend yield of 18.1%, which is attractive to investors seeking regular income.

Financial Performance

Cryo-Cell International reported a beat on revenue and EBITDA.

Negative Factors

Financial Estimates

Higher litigation expenses and Duke royalty expenses have led to a reduction in financial estimates.

Litigation

The ongoing arbitration against Duke University could potentially impact the company's financial position, with management believing damages could exceed $100M.

Litigation Costs

Higher expenses are expected due to litigation costs and Duke royalty expenses being accrued.

Cryo-Cell International Business Overview & Revenue Model

Company Description

Cryo-Cell International (CCEL) is a biotechnology company specializing in the collection, processing, and cryopreservation of stem cells derived from umbilical cord blood and tissue. Operating within the healthcare and biotechnology sectors, Cryo-Cell International offers services primarily geared towards expectant parents, providing them with the opportunity to store their newborns' stem cells for potential future medical use. The company's core services include umbilical cord blood banking, cord tissue banking, and related stem cell storage solutions.

How the Company Makes Money

Cryo-Cell International generates revenue primarily through its stem cell banking services. The company charges clients a fee for the collection, processing, and long-term storage of stem cells from umbilical cord blood and tissue. This includes an initial processing fee and recurring annual storage fees. Additionally, the company may earn revenue from offering related services, such as the retrieval and use of stored stem cells for medical treatments, as well as from potential partnerships or collaborations with healthcare providers and research institutions interested in utilizing stem cell technology. Strategic alliances and licensing agreements can also contribute to its revenue streams, although specific details on partnerships are not available.

Cryo-Cell International Financial Statement Overview

Summary

Cryo-Cell International demonstrates moderate growth and operational improvements, but faces challenges with high leverage and negative equity. Cash flow remains robust, providing a cushion for financial obligations. The company needs to address balance sheet weaknesses to enhance financial health.

Income Statement

Cryo-Cell International shows steady revenue growth over the years with a recent increase in gross profit margin to 75.80% TTM. However, net profit margin remains thin at 0.40% TTM, indicating limited profitability. EBIT and EBITDA margins improved to 11.57% and 12.42% TTM respectively, reflecting better operational efficiency.

Balance Sheet

The balance sheet highlights a negative stockholders' equity of -$14.66 million TTM, raising concerns about financial stability. The debt-to-equity ratio is not applicable due to negative equity, and the equity ratio is negative, indicating high leverage risks. However, there is a moderate reduction in total debt.

Cash Flow

Operating cash flow is strong at $7.32 million TTM, with a free cash flow to net income ratio of 31.96, indicating good cash generation relative to earnings. Free cash flow growth is positive, supporting future investment opportunities.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
32.10M	31.99M	31.34M	30.34M	28.88M	31.15M
	Gross Profit
24.33M	24.04M	22.90M	21.54M	19.90M	21.49M
	EBIT
3.72M	3.48M	-12.30M	4.02M	4.00M	7.66M
	EBITDA
3.99M	1.42M	-10.42M	6.65M	5.32M	7.22M
	Net Income Common Stockholders
128.71K	402.10K	-9.52M	2.77M	2.08M	3.62M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.48M	3.50M	980.25K	1.72M	8.34M	10.45M
	Total Assets
64.38M	64.68M	61.22M	64.89M	60.66M	46.20M
	Total Debt
13.86M	12.93M	10.90M	11.61M	2.82M	6.24M
	Net Debt
13.64M	12.37M	10.49M	9.91M	-5.44M	-4.12M
	Total Liabilities
79.04M	77.89M	72.25M	66.41M	56.48M	48.87M
	Stockholders Equity
-14.66M	-13.22M	-11.03M	-1.52M	4.18M	-2.67M
Cash Flow		Free Cash Flow
4.11M	3.61M	1.28M	-8.60M	974.92K	8.02M
	Operating Cash Flow
7.32M	6.01M	8.92M	8.57M	7.93M	8.47M
	Investing Cash Flow
-4.82M	-4.88M	-8.14M	-15.28M	-6.95M	357.49K
	Financing Cash Flow
-2.52M	-979.12K	-2.07M	147.86K	-3.07M	-5.00M

Cryo-Cell International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Negative. The current price of 5.04 is below the 20-day moving average (MA) of 5.38, below the 50-day MA of 5.99, and below the 200-day MA of 6.74, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 38.05 is Neutral, neither overbought nor oversold. The STOCH value of 25.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCEL.

Cryo-Cell International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	66 Neutral	$77.91M	2.46	-58.97%	―	36.45%	―
Sector *	52 Neutral	$5.15B	3.56	-42.52%	2.83%	14.56%	-0.53%
CCEL	51 Neutral	$40.77M	403.60	93.38%	9.91%	2.33%	―
KRON	46 Neutral	$43.91M	―	-59.49%	―	21.15%	46.44%
GANX	46 Neutral	$54.33M	―	-204.95%	―	-100.00%	44.28%
STTK	43 Neutral	$41.68M	―	-71.90%	―	69.65%	27.98%

Cryo-Cell International Corporate Events

Cryo-Cell International Declares Reduced Quarterly Dividend

On May 7, 2025, Cryo-Cell International‘s Board of Directors declared a reduced quarterly cash dividend of $0.15 per share, reflecting the current economic environment and capital allocation alternatives. This decision, announced on May 8, 2025, may impact shareholder returns and indicates a cautious approach to financial management amid uncertain economic conditions.

Spark’s Take on CCEL Stock

According to Spark, TipRanks’ AI Analyst, CCEL is a Neutral.

Cryo-Cell International’s overall stock score reflects moderate financial performance with strong cash flow but significant balance sheet issues, including negative equity. Technical indicators suggest a bearish trend, and the stock may be overvalued based on its P/E ratio, though its high dividend yield could attract some investors.

To see Spark’s full report on CCEL stock, click here.